Metraipolis › archive › dc_64eeb7d8174d

Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema — Europe PMC PMID:41195186

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41195186
DOI
10.3389/fmed.2025.1662735
License (as archived)
solo-consultazione
Archived
2026-11-09T04:42:40.128Z
SHA-256 of the archived text
43d103cf47c6e4f72be3951ede43f90b72b256c8f9bcc42c5eb347504f61e63e
Stable URL of this page
https://metraipolis.com/documento/dc_64eeb7d8174d

How to cite

Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema — Europe PMC PMID:41195186 — Europe PMC (en), https://europepmc.org/article/MED/41195186 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_64eeb7d8174d (Metraipolis archive dc_64eeb7d8174d, sha256 43d103cf47c6e4f72be3951ede43f90b72b256c8f9bcc42c5eb347504f61e63e)
BibTeX
@misc{dc64eeb7d8174d,
  title = {Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema — Europe PMC PMID:41195186},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41195186},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_64eeb7d8174d; sha256 43d103cf47c6e4f72be3951ede43f90b72b256c8f9bcc42c5eb347504f61e63e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41195186. Agents can read the archived copy with the MCP tool read_document.